Podcasts about tirzepatide

Credits: 0.25 AMA PRA Category 1 Credit™   CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-451 Overview: The obesity epidemic has fueled a demand for weight loss medications. Trials have directly compared medications—specifically glucagon-like peptide-1 receptor agonists (GLP-1 RAs)—with a recent study doing just that. Tune in as we explore the evidence comparing semaglutide and tirzepatide for weight loss outcomes up to 1 year. Episode resource links: Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Intern Med. 2024;184(9):1056-1064.  Moiz A, Filion KB, Toutounchi H, et al. Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss Among Adults Without Diabetes : A Systematic Review of Randomized Controlled Trials. Ann Intern Med. 2025;178(2):199-217.  Wen J, Syed B, Nadora D, et al. Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Direct Comparative Studies. Endocrinol Diabetes Metab. 2025;8(3):e70045.  Guest: Alan M. Ehrlich, MD, FAAFP Music Credit: Matthew Bugos Thoughts? Suggestions? Email us at FranklySpeaking@pri-med.com  

I'm leaving for my yearly Disney trip for the T1D conference, and y'all — nothing will humble you more than a three-way dressing-room mirror. I tried on one of those athletic dresses and BAM: back-fat in the mirror I'd never noticed before. Cue the body image vacation panic. But I refused to let bad lighting and spandex steal my trip. In this episode, I tell the whole embarrassing story, exactly how I knocked myself out of that spiral, and why you absolutely cannot put your life on hold until the scale says so.

Sick of trying fad diets that just don't seem to work for you? Find out how to simplify your approach and succeed by learning and applying the principles of weight management.  How to make calories work for you Which proteins are better than others and when to eat protein Preserving lean muscle while losing body fat "Dirty" vs "Clean" diets Including desert and candy during a weight loss journey   APEX RX https://apexrx.net   Jesse Frank https://www.lvrgfit.com jesse.dfrank@gmail.com   Charlie Seltzer https://drseltzerlifestylemedicine.com info@drseltzerweightloss.com

AI accelerates drug discovery while steroids turn teens into aggressive strangers. Dr. Michael Israetel explores our pharmaceutical crossroads here!Full show notes and resources can be found here: jordanharbinger.com/1209What We Discuss with Michael Israetel:GLP-1 drugs like Tirzepatide offer massive health benefits beyond weight loss — reducing inflammation, improving brain health, and decreasing addiction behaviors, even for people already in good shape.Steroids don't just amplify personality — they specifically amplify masculine traits like aggression and reduce empathy. Starting young can permanently rewire your brain's emotional and social processing.AI is about to revolutionize medicine by testing millions of drug candidates virtually, creating treatments 10x more effective with 10x fewer side effects. We're entering the pharmaceutical iPhone moment.The "only take drugs when sick" mindset worked in the 20th century, but is becoming dangerously outdated — like refusing elevators because you prefer human operators.When your diet plateaus, take a week-long break eating at maintenance. Your stress hormones will drop, body water will flush out, and you'll often look leaner than before.And much more...And if you're still game to support us, please leave a review here — even one sentence helps! Sign up for Six-Minute Networking — our free networking and relationship development mini course — at jordanharbinger.com/course!Subscribe to our once-a-week Wee Bit Wiser newsletter today and start filling your Wednesdays with wisdom!Do you even Reddit, bro? Join us at r/JordanHarbinger!This Episode Is Brought To You By Our Fine Sponsors:Saily: 15% off: saily.com/jordanharbinger, code JORDANHARBINGERDripDrop: 20% off: DripDrop.com, code JORDANLinkedIn Jobs: Post your job for free: linkedin.com/jordanQuince: Free shipping & 365-day returns: quince.com/jordanBetterHelp: 10% off first month: betterhelp.com/jordanSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Special edition of the JAMA Editor's Summary featuring the JAMA Network articles published at the 2025 European Society of Cardiology Congress. Hosted by JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, with JAMA Executive Editor Gregory Curfman, MD, JAMA Senior Editor Philip Greenland, MD, and JAMA Cardiology Editor Robert O. Bonow, MD, MS. Related Content: Remote Screening for Asymptomatic Atrial Fibrillation Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation Systolic Blood Pressure and Microaxial Flow Pump–Associated Survival in Infarct-Related Cardiogenic Shock Helicobacter pylori Screening After Acute Myocardial Infarction Physiology-Guided Complete Revascularization in Older Patients With Myocardial Infarction Fractional Flow Reserve–Guided Complete vs Culprit-Only Revascularization in Non–ST-Elevation Myocardial Infarction and Multivessel Disease Transcatheter or Surgical Treatment of Patients With Aortic Stenosis at Low to Intermediate Risk Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction Bivalent RSV Prefusion F Protein–Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults Risk of Myocarditis or Pericarditis With High-Dose vs Standard-Dose Influenza Vaccine Clonal Hematopoiesis and Risk of New-Onset Myocarditis and Pericarditis Participation of Women in Cardiovascular Trials From 2017 to 2023 Prevalence, Determinants, and Time Trends of Cardiovascular Health in the WHO African Region

Welcome back to Ozempic Weightloss Unlocked, the show that brings listeners the most current news, research, and perspectives on Ozempic, the medication that has transformed weight loss conversations everywhere.Ozempic, generically known as semaglutide, was originally approved for type two diabetes by the FDA in 2017. Its follow-up, Wegovy, hit the market in 2021 explicitly for chronic weight management. Both drugs belong to a class called glucagon-like peptide-one receptor agonists. These medications work by mimicking a naturally occurring hormone that helps the body regulate blood sugar after meals while also reducing appetite by slowing the digestive process. Many patients taking Ozempic weekly have seen impressive reductions in body weight—up to 16 percent, according to data highlighted by the American Journal of Managed Care.The popularity of Ozempic exploded when its weight loss effects were amplified on social media and through celebrity endorsements. Demand surged, and global interest grew as more people sought medical solutions outside of diet and exercise alone. But Ozempic is not just hype—it's backed by multiple clinical trials and growing medical consensus, though not without debate.Researchers continue to push the boundaries, and major updates are underway. According to Fox News Digital and the Times of India, scientists at Tufts University have developed a next-generation experimental drug aimed at delivering weight loss of up to thirty percent—nearly matching surgical outcomes but without the operation. This new compound works across four hormone pathways: GLP-1, GIP, glucagon, and peptide YY, aiming to deliver robust weight loss with fewer side effects like nausea and muscle loss. The “quadruple-action” drug is still in early preclinical stages, tested only in cells—not yet in humans or animals—but represents a bold step towards more personalized, gentle, and sustainable weight management therapies.For now, single-hormone agents like Ozempic remain widely prescribed. Experts urge those on GLP-1 medications to partner closely with their clinicians, focusing on daily protein, hydration, and resistance training to mitigate risks such as muscle loss and malnutrition. Nutritional support is key, as well as regular follow-ups.Alongside medical progress, litigation and warnings continue to surface. The Lawsuit Information Center reports that thousands of claimants have entered into multidistrict litigation over Ozempic and similar drugs, citing side effects like gastroparesis, or stomach paralysis, and rare forms of vision loss including neovascular age-related macular degeneration and optic neuropathy. A 2025 study out of the University of Toronto found semaglutide users twice as likely to develop macular degeneration compared to others—a small risk, but real and statistically significant. Another concern comes from JAMA Otolaryngology–Head & Neck Surgery, showing a possible increased risk of thyroid cancer among GLP-1 agonist users. The defense argues that many of these side effects are rare, and some findings may be linked to increased medical surveillance, rather than the drug itself. Physicians and patients are encouraged to weigh these risks alongside the benefits and always discuss options thoroughly before starting treatment.As for what comes next, listeners should keep an eye on innovations underway: oral drugs like orforglipron, combination therapies such as CagriSema, and monthly injectables from major firms—all targeting more effective weight loss with easier dosing and fewer downsides. Tirzepatide, branded as Zepbound, is currently considered one of the most potent with trial data showing up to twenty-one percent body weight loss.The obesity epidemic is far from solved, but the next wave of treatments could make weight loss less about suffering and more about smart science. Whether listeners are considering Ozempic, awaiting newer options, or just tuning in for updates, the biggest takeaway is this: work with a trusted healthcare provider, stay informed about the latest findings, and balance medication with healthy lifestyle habits.Thank you for tuning in to Ozempic Weightloss Unlocked. Do not forget to subscribe and share. This has been a Quiet Please production—for more, check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

I'm back from my summer break, and today we're talking about what it really means to come out of survival mode and step into a new season of life. When you're just trying to make it through, the world feels blurry. You don't even notice the little things piling up around you. But once you start to shift, it's like everything comes back into focus: the appointments you've been putting off, the house that suddenly needs cleaning, and most importantly, you.In this episode, I'm sharing a summer recap (including an upcoming Disney trip I didn't think would happen), how back-to-school season has me reflecting on my own routines, and why fall is the perfect reminder that change can be beautiful.

At ESC 2025, a pair of presentations highlighted the ongoing debate over cardiovascular risk reduction with semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound), yielding conflicting signals that clinicians will need to interpret carefully. In this special edition episode, cohosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, explore these studies: SURMOUNT-5 and STEER. A post hoc analysis of SURMOUNT-5 compared the 10-year predicted CV risk reduction between the 2 agents. Using the Framingham Risk Calculator in 751 patients with obesity, tirzepatide was associated with greater benefit than semaglutide. From baseline risks of ~9%, tirzepatide was projected to lower absolute 10-year CV risk by 2.4% (23% relative reduction) compared with 1.4% (13% relative reduction) for semaglutide. Investigators attributed the advantage largely to greater weight and glycemic reductions. In contrast, the STEER study, a real-world analysis of more than 21,000 patients with a mean follow-up of 8.5 months, suggested semaglutide was associated with lower rates of major adverse cardiovascular events (MACE) than tirzepatide. Semaglutide users had a 29% risk reduction in nonfatal MI, nonfatal stroke, or CV death compared with tirzepatide. Limitations included short follow-up, relatively few CV events, and the inherent confounding of observational data. Both Isaacs and Bellini emphasized that while weight and glycemic improvements with tirzepatide appear robust, CV benefits may be molecule-specific. The ongoing SURPASS-CVOT, comparing tirzepatide with dulaglutide, should provide more clarity when full data are released at EASD. In the interim, the hosts advised prescribing based on labeled indications supported by randomized outcomes data—semaglutide for CV and kidney risk reduction, tirzepatide for obesity and sleep apnea—while awaiting definitive trial results. Relevant disclosures for Isaacs include Eli Lilly and Company, Novo Nordisk, Sanofi, Abbott Diabetes Care, Dexcom, Medtronic, and others. Relevant disclosures for Bellini include Abbott Diabetes Care, MannKind, Provention Bio, and others. References: Mamas M. SURMOUNT-5: Tirzepatide compared to Semaglutide in obesity for 10-year CVD risk reduction .Presented at the European Society of Cardiology (ESC) Congress 2025. Madrid, Spain. August 29- September 1, 2025. Novo Nordisk. Novo Nordisk's Wegovy® cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular disease. Novo Nordisk. Published August 31, 2025. Accessed September 5, 2025. https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916422

Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update   discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. Welcome to diabetes core update where every month we go over the most important articles to come out in the field of diabetes. Articles that are important for practicing clinicians to understand to stay up with the rapid changes in the field.  This issue will review:   1.     Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity  - NEJM   2.     Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3)– Lancet Diabetes Endocrinology    3.     Nutritional priorities to support GLP-1 therapy for Obesity – A Joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society - American Journal of Clinical Nutrition 4.     Gradual Titration of Semaglutide Results in Better Treatment Adherence and Fewer Adverse Events – Diab Care 5.     Tirzepatide as Compared with Semaglutide for the Treatment of Obesity – NEJM For more information about each of ADA's science and medical journals, please visit Diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health

Special edition of the JAMA Editor's Summary featuring the JAMA Network articles published at the 2025 European Society of Cardiology Congress. Hosted by JAMA Editor in Chief Kirsten Bibbins-Domingo, PhD, MD, MAS, with JAMA Executive Editor Gregory Curfman, MD, JAMA Senior Editor Philip Greenland, MD, and JAMA Cardiology Editor Robert O. Bonow, MD, MS. Related Content: Remote Screening for Asymptomatic Atrial Fibrillation Long-Term Anticoagulation Discontinuation After Catheter Ablation for Atrial Fibrillation Systolic Blood Pressure and Microaxial Flow Pump–Associated Survival in Infarct-Related Cardiogenic Shock Helicobacter pylori Screening After Acute Myocardial Infarction Physiology-Guided Complete Revascularization in Older Patients With Myocardial Infarction Fractional Flow Reserve–Guided Complete vs Culprit-Only Revascularization in Non–ST-Elevation Myocardial Infarction and Multivessel Disease Transcatheter or Surgical Treatment of Patients With Aortic Stenosis at Low to Intermediate Risk Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction Bivalent RSV Prefusion F Protein–Based Vaccine for Preventing Cardiovascular Hospitalizations in Older Adults High-Dose vs Standard-Dose Influenza Vaccine and Cardiovascular Outcomes in Older Adults Risk of Myocarditis or Pericarditis With High-Dose vs Standard-Dose Influenza Vaccine Clonal Hematopoiesis and Risk of New-Onset Myocarditis and Pericarditis Participation of Women in Cardiovascular Trials From 2017 to 2023 Prevalence, Determinants, and Time Trends of Cardiovascular Health in the WHO African Region

In this episode, Tina returns from a summer break to discuss her experience with microdosing GLP-1, particularly with the peptide Tirzepatide. She shares insights on GLP-1's misconceptions, its benefits for metabolism, and its impact on women in perimenopause and menopause. Emphasizing the importance of individualized medical advice, she shares details of her journey using peptides for her chronic condition, inflammatory issues, and appetite control. Additionally, she introduces her preferred telehealth provider and upcoming programs to support women considering peptide usage. Here's what you'll learn: - How my ulcerative colitis journey led me to try peptides - The mistakes I made buying and mixing peptides at home - The misconceptions I had about GLP-1s and what I learned instead - Why microdosing a GLP-1 might help with inflammation, blood sugar, and appetite - The surprising benefits for women in perimenopause and menopause - How my eating habits completely changed in just eight weeks - Why caffeine and alcohol suddenly aren't as appealing - My current peptide and supplement stack, and what I plan to keep long term - What's next for me and how you can learn more if you're curious Free Training: Hormone-Driven Fat Loss Method: https://carrotsncake.kit.com/5909f18b13 Peptides for Women course: https://carrotsncake.com/offers/3Q7wttmr?coupon_code=PROTOCOL19 Our trusted telehealth partner: https://elliemd.com/tinahaupert https://carrots-n-cake.mykajabi.com/fit+fueled Connect with Tina Haupert: https://carrotsncake.com/ Facebook: Carrots 'N' Cake https://www.facebook.com/carrotsncake Instagram: carrotsncake https://www.instagram.com/carrotsncake YouTube: Tina Haupert https://www.youtube.com/user/carrotsncake About Tina Haupert: Tina Haupert is the owner of Carrots ‘N' Cake as well as a Certified Nutrition Coach and Functional Diagnostic Nutrition Practitioner (FDN-P). Tina and her team use functional testing and a personalized approach to nutrition to help women find balance within their diets while achieving their body composition goals.

Peptides Vs. Steroids: The Safer Road to Building Muscle & Defeating Fat Amslifestylemedicine.com/ About the Guest(s): Dr. Maureen Gibbons, affectionately known as Dr. Mo, is an emergency medicine and obesity medicine board-certified physician turned lifestyle medicine entrepreneur. She is the founder of AMS Lifestyle Medicine, a practice dedicated to helping patients reclaim food freedom, improve metabolic health, and lead fulfilling lives. Dr. Mo is also an accomplished author, guiding individuals through transformative health journeys with works like her latest book, "Freedom to Shift: Lose the Weight and Gain Your Freedom." Episode Summary: In this enlightening episode of The Chris Voss Show, Dr. Mo graces the podcast to share her riveting journey from being an emergency medicine practitioner to a leading figure in lifestyle medicine. Host Chris Voss humorously opens the session, promising listeners an engaging and educative rollercoaster, with guests that are sure to leave listeners both informed and inspired. Dr. Mo delves deep into her personal struggles with weight and eating habits, revealing how her own experiences motivated her to pivot into the field of lifestyle medicine. Tackling a variety of topics, Dr. Mo elaborates on the physiological and habitual causes of weight struggles, highlighting the innovative solutions her practice offers. From cutting-edge medications like Tirzepatide, better known as Manjaro, to the significant impact of hormones on weight and health, Dr. Mo provides valuable insights into how her practice helps patients break free from their chains of food obsession. Through AMS Lifestyle Medicine, Dr. Mo and her team offer telehealth services, including weight management and TRT programs, empowering people to lead healthier, more balanced lives by providing personalized support and actionable strategies. Key Takeaways: Dr. Mo transitioned from a successful career in emergency medicine to focus on lifestyle medicine, inspired by her personal battles with food and weight. Her practice, AMS Lifestyle Medicine, uses innovative treatments like Tirzepatide and lifestyle coaching to help patients overcome metabolic and weight challenges. Hormonal imbalances are pivotal in weight management, and medications like Tirzepatide can effectively address these issues. Dr. Mo emphasizes the importance of understanding the psychological and habitual triggers of weight issues, offering a holistic approach to treatment. Telehealth services provided by AMS Lifestyle Medicine offer patients nationwide access to personalized care and innovative weight management solutions. Notable Quotes: "I knew that I had credentialed a couple years ago because I had someone in COVID, one of my good friends, replaced her income through telehealth." "Medication's a tool, you know, and that's the big thing in the media. Oh, it's a skinny shot. It's a magic pill. I wish." "For a lot of people, and like I said, semaglutide is a great drug for a lot of people, but for some it's just not." "I'm counting the collagen. Leave me alone." "If you're in there and you're like, yeah, I think you guys are crazy and I don't really like the way you do things. You don't pay."

Metformin for Treatment of Knee Osteoarthritis in Patients With Overweight or ObesityOnce-Weekly Semaglutide in Persons with Obesity and Knee OsteoarthritisSemaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit www.sensible-med.com/subscribe

In this episode of the RWS Clinician's Corner, Margaret Floyd Barry sits down with Dr. Tyna Moore—renowned naturopathic physician, chiropractor, and international speaker with almost 30 years of experience in holistic and regenerative medicine. Dr. Tyna is known for her bold approach to metabolic health, especially her unique use of GLP-1 agonists like semaglutide, not just for weight loss but as powerful tools for longevity, healing, and resilience. Dr. Tyna pulls back the curtain on the true clinical potential of these peptides, busting myths and exploring the nuance lost in today's clickbait headlines.   In this interview, we discuss:   The science behind GLP-1s and GLP-1 Agonists (including mechanism of action and effects) Microdosing/personalized dosing of GLP-1s, including clinical uses beyond weight loss The concept of “cycling” versus lifelong usage (compared to hormone therapy) Potential side effects and dosing management (including contraindications and safety) Compounded GLP-1s: access, regulations, and practicalities Industry resistance, misinformation, and social dynamics Using GLP-1s during gut healing protocols and the limits of natural alternatives The Clinician's Corner is brought to you by Restorative Wellness Solutions.  Follow us: https://www.instagram.com/restorativewellnesssolutions/    Connect with Dr. Tyna Moore: Website: http://www.drtyna.comInstagram: https://www.instagram.com/drtyna/ YouTube: https://www.youtube.com/@drtyna   Click here for Dr. Tyna's Free 4-part video Series, GLP-1 Uncovered. This video series concludes with an offer for her course, GLP-1s Done Right University. Enter coupon code MARGARET to receive a special discount: https://www.drtyna.com/ozempicuncovered   Or, to go directly to the course, GLP-1s Done Right University, click here and enter the same coupon code (MARGARET) to get started.  Timestamps: 00:00 Regenerative Medicine and Hormone Therapy  05:57 Functional Medicine Truth vs. Propaganda  14:17 Regenerative Therapy Requires Low Inflammation  16:08 Widespread Cardiometabolic Health Crisis  22:16 "Managing Health Challenges with Medication"  30:29 "Low-Dose Approach for Diabetes Management"  36:16 "Empowering Patients Through Education"  38:58 Custom Medication Dosing Benefits  44:43 503B Compounding Pharmacies Shutdown  52:51 Understanding Peptides in Modern Healthcare  57:15 Biliary Concerns in GLP-1 Use  59:14 Liver Health and Supplement Advice  01:06:57 Optimizing Gut Microbiome Strategies  01:10:17 "GLP-1 for Health Improvement" 01:15:29 "Rediscovering Physical Fitness" Speaker bio:    With nearly thirty years immersed in the medical field, Dr. Tyna Moore is an expert in holistic regenerative medicine and resilient metabolic health. She is licensed as a Naturopathic Physician and a Chiropractor, drawing on knowledge from both traditional and alternative fields of science and medicine to provide a comprehensive perspective to individuals striving to enhance their health and wellbeing. Dr. Tyna holds degrees from the National College of Natural Medicine, an esteemed naturopathic medical school, and the University of Western States Chiropractic College. Her work is not just about treating symptoms, it's about understanding and healing root causes to build a robust foundation for long term wellbeing. She is well known for her fierce and open-minded exploration of the peptide, Semaglutide/Ozempic, as a longevity tool for healing. Dr. Tyna champions medical autonomy and individual accountability, and she is on a mission to help as many people as possible experience the freedom and joy that health brings.   As the host of The Dr. Tyna Show Podcast, a top ranking podcast in the health and wellness space, and an international speaker, she is dedicated to empowering others to take control of their wellbeing, heal their metabolic health, and build strength and resilience. Her cornerstone recommendations for every patient and listener: weight lifting and sunshine. Additionally, she extends her expertise to support fellow doctors in cultivating their online practices, helping them transition away from the insurance-centric model to reclaim time, financial stability, and freedom.   Dr. Tyna lives in Oregon with her husband and daughter, and is a proud dog mama. Keywords: GLP-1 agonists, semaglutide, tirzepatide, peptides, regenerative medicine, metabolic health, weight loss strategies, microdosing, hormone replacement therapy, insulin resistance, appetite suppression, personalized dosing, compounding pharmacies, side effects, gut health, SIBO (small intestinal bacterial overgrowth), slow motility, inflammation, functional medicine, neuroregeneration, autoimmune conditions, BPC-157, muscle mass, pharmaceutical dosing, diabetes management, cardiovascular health, leaky gut, obesity, perimenopause, patient empowerment, cycling peptides   Disclaimer: The views expressed in the RWS Clinician's Corner series are those of the individual speakers and interviewees, and do not necessarily reflect the views of Restorative Wellness Solutions, LLC. Restorative Wellness Solutions, LLC does not specifically endorse or approve of any of the information or opinions expressed in the RWS Clinician's Corner series. The information and opinions expressed in the RWS Clinician's Corner series are for educational purposes only and should not be construed as medical advice. If you have any medical concerns, please consult with a qualified healthcare professional. Restorative Wellness Solutions, LLC is not liable for any damages or injuries that may result from the use of the information or opinions expressed in the RWS Clinician's Corner series. By viewing or listening to this information, you agree to hold Restorative Wellness Solutions, LLC harmless from any and all claims, demands, and causes of action arising out of or in connection with your participation. Thank you for your understanding.  

From diabetes care to weight loss trends, GLP-1 agonists are everywhere. In this episode, we unpack the science, social media hype, ethical dilemmas, and side effects surrounding Ozempic, Wegovy, and more. Featuring Dr. Jodie Gee, a Clinical Assistant Professor here at University of Houston College of Pharmacy, and a Ambulatory Care Clinical Pharmacists at Vecino's Denver Harbor Family Clinic, we explore her insights on the role of GLP-1As in patient care. Stay at the end for an in-depth highlight of the newly FDA-approved tirzepatide!

Jessica Brennan, started in the fitness industry 10 years ago as a fitness instructor and personal trainer, realized early on that achieving health goals went beyond physical activity. This realization led Jessica to pursue certifications in nutrition, hormone specialist, and gut health specialist, aiming to address health challenges holistically. Working closely with Karen at Hormone Solutions, Jessica is dedicated to sharing her expertise with women globally. Her areas of expertise include bodybuilding, women's hormone health, personalized nutrition, peptide therapy, and chronic illness management. Jessica is with me this time to discuss our one-year anniversary of being on weight loss peptides. We also created our weight loss peptide group about a year ago which, in addition to our own experiences, has provided us many different points of view on the ups and downs that members face. We'll share personal stories and lessons learned from our community of over 200 members, discussing the use of GLP-1 peptides, strategies for minimizing side effects, and the importance of muscle preservation. We also get into how peptides can improve sleep, athletic performance, and hormonal balance. In this episode: How weight loss peptides and hormone optimization can transform wellness and fitness goals. Optimizing peptide regimens to minimize side effects and prevent muscle loss. Why holistic health approaches are crucial for long-term wellness beyond just weight reduction. Why addressing foundational health practices enhances the success of hormonal treatments. How hormone balance plays a crucial role in weight control and muscle preservation, especially during menopause. Why effort and the right mindset are non-negotiables for achieving fitness goals. How the CAROL Bike can aid in maximizing workout efficiency while using peptides. Why women should progress beyond comfort zones in weightlifting for muscle development. How peptides synergize with training, emphasizing workout efficiency for busy individuals. Why long-term peptide use may be necessary for ongoing health maintenance and weight management. How guilt associated with medication for weight control should be reframed as a preventive health measure. How GLP-1 agonists impact the immune system, mental health, and metabolic functions. Tirzepatide's positive influence on thyroid function. How addressing hormonal imbalances in conjunction with weight loss efforts leads to better outcomes. Why community support can be transformative in the health and fitness journey.   Sponsors Coupon KM20 to get 20% off your order of Vitali Skin Care! Get 40% off your Cozy Earth Bed Sheet with coupon code HORMONES     Are you in peri or post menopause and looking to optimize your hormones and health? At Hormone Solutions, we offer telemedicine services and can prescribe in every U.S. state, as well as in British Columbia, Alberta, and Ontario in Canada.   Visit karenmartel.com to explore our comprehensive programs: Bioidentical Hormone Replacement Therapy Individualized Weight Loss Programs  Peptide Therapy for weight loss    Interested in our NEW Peptide Weight Loss Program? Join today and get all the details here.   Join our Women's Peri and Post Menopause Group Coaching Program, OnTrack, TODAY!   To our nursing audience members, our podcasts qualify for nursing CE @ RNegade.pro. Provide # CEP17654.   Your host: Karen Martel Certified Hormone Specialist, Transformational Nutrition Coach, & Weight Loss Expert   Karen's Facebook Karen's Instagram

TakeawaysThe podcast features Dr. Grant Tinsley, a body composition expert.The discussion revolves around a case series on body composition effects.GLP-1 receptor agonists are a focus of the research.The importance of resistance training in weight loss is emphasized.Patient case studies provide insights into individual experiences.The first patient lost a significant amount of fat mass while preserving lean mass.The second patient achieved remarkable body composition changes in a short time.The third patient showed positive changes over a longer duration.The need for more randomized trials is highlighted.The conversation underscores the role of exercise and nutrition in weight management.Tap or Click here to see more from Dr. GrantTap here for scientific references in this episode.

Dr. Gillett and James O'Hara discuss a new study on TizepatideFor High-quality labs:► http://sagebio.com/For information on the Gillett Health clinic, lab panels, and health coaching:► https://GillettHealth.comFollow Gillett Health for more content from James and Kyle► https://instagram.com/gilletthealth► https://www.tiktok.com/@gilletthealth► https://twitter.com/gilletthealth► https://www.facebook.com/gilletthealthFollow Kyle Gillett, MD► https://instagram.com/kylegillettmdFollow James O'Hara, NP► https://Instagram.com/jamesoharanpFor 10% off Gorilla Mind products including SIGMA: Use code “GH10”► https://gorillamind.com/For discounts on high-quality supplements►https://www.thorne.com/u/GillettHealth#weightloss #trt #health #glp1 #testosteroneAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

In this special episode on Obstructive Sleep Apnea our host, Dr. Neil Skolnik will discuss treatment of OSA. In Part 1 we discussed and overview of OSA, in Part 2 we discussed making the diagnosis will, and Part 4 will look at cases. This special episode is supported by an independent educational grant from Lilly. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Dr. Sanjay Patel, M.D, Professor of Medicine, Epidemiology, & Clinical and Translational Science, and Director of the Center for Sleep and Cardiovascular Outcomes Research; Medical Director of the Comprehensive Sleep Disorders Program, University of Pittsburgh Medical Center Selected references: Diagnosis and Management of Obstructive Sleep Apnea - A Review. JAMA. 2020;323(14):1389-1400 Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med 2024;391:1193-1205

Liver, Lipids, and the Left Ventricle

Dr. Robert Baron explores current strategies for treating obesity, emphasizing evidence-based approaches to diagnosis, lifestyle change, medication, and long-term weight maintenance. He explains the limitations of body mass index (BMI) as a diagnostic tool and highlights the importance of assessing both excess fat and its health consequences. He reviews dietary principles, including calorie reduction, avoiding added sugars, and the importance of sustainable habits over specific diet types. He also discusses the role of physical activity—particularly strength training—for preserving muscle and improving long-term outcomes. Baron evaluates weight loss medications such as semaglutide and tirzepatide, noting their benefits, side effects, and the need for continued use to maintain weight loss. [Health and Medicine] [Show ID: 40757]

Dr. Robert Baron explores current strategies for treating obesity, emphasizing evidence-based approaches to diagnosis, lifestyle change, medication, and long-term weight maintenance. He explains the limitations of body mass index (BMI) as a diagnostic tool and highlights the importance of assessing both excess fat and its health consequences. He reviews dietary principles, including calorie reduction, avoiding added sugars, and the importance of sustainable habits over specific diet types. He also discusses the role of physical activity—particularly strength training—for preserving muscle and improving long-term outcomes. Baron evaluates weight loss medications such as semaglutide and tirzepatide, noting their benefits, side effects, and the need for continued use to maintain weight loss. [Health and Medicine] [Show ID: 40757]

Dr. Robert Baron explores current strategies for treating obesity, emphasizing evidence-based approaches to diagnosis, lifestyle change, medication, and long-term weight maintenance. He explains the limitations of body mass index (BMI) as a diagnostic tool and highlights the importance of assessing both excess fat and its health consequences. He reviews dietary principles, including calorie reduction, avoiding added sugars, and the importance of sustainable habits over specific diet types. He also discusses the role of physical activity—particularly strength training—for preserving muscle and improving long-term outcomes. Baron evaluates weight loss medications such as semaglutide and tirzepatide, noting their benefits, side effects, and the need for continued use to maintain weight loss. [Health and Medicine] [Show ID: 40757]

Dr. Robert Baron explores current strategies for treating obesity, emphasizing evidence-based approaches to diagnosis, lifestyle change, medication, and long-term weight maintenance. He explains the limitations of body mass index (BMI) as a diagnostic tool and highlights the importance of assessing both excess fat and its health consequences. He reviews dietary principles, including calorie reduction, avoiding added sugars, and the importance of sustainable habits over specific diet types. He also discusses the role of physical activity—particularly strength training—for preserving muscle and improving long-term outcomes. Baron evaluates weight loss medications such as semaglutide and tirzepatide, noting their benefits, side effects, and the need for continued use to maintain weight loss. [Health and Medicine] [Show ID: 40757]

Thank you for listening to The Peptide Podcast. If you enjoyed the show and want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going.  Today, we're diving into one of the most talked-about topics in health and weight loss right now: GLP-1 medications like semaglutide and the newer dual GIP/GLP-1s like tirzepatide. You've probably seen the headlines, scrolled past a few TikToks, or heard a friend mention it — but with all that noise comes a lot of confusion, half-truths, and flat-out myths. Today we're breaking it all down. What's real? What's hype? And what do you actually need to know if you're using these medications — or thinking about it? Let's separate science from scare tactics and get to the truth, one myth at a time. Myth #1: GLP-1s Cause Dangerous Muscle Loss The claim:  “GLP-1s cause massive muscle loss.” Truth: This is an overstatement. Some loss of lean mass is normal with any kind of weight loss — whether it's through diet, medication, or surgery. What studies show is that with medications like semaglutide (Wegovy) and tirzepatide (Zepbound), about 20–25% of the total weight lost comes from lean mass, and the rest is fat — which is exactly what we're targeting in obesity treatment. That 20–25% figure isn't unique to these meds; it's actually pretty typical in weight loss without focused resistance training or optimized protein intake. You may also hear “You'll lose all your muscle and become frail on GLP-1s.” Truth: You won't “lose all your muscle.” In fact, muscle loss is preventable by maintaining adequate protein intake, resistance training, and managing weight loss pace. Furthermore, many patients gain strength and mobility as excess weight comes off. And lastly, my favorite myth is “You can't preserve muscle on GLP-1s.” Truth: That's completely false — muscle loss isn't inevitable on GLP-1s if you take the right approach. You can absolutely preserve muscle by making a few intentional choices: aim for enough protein each day (a good goal is around 0.8 grams per pound of body weight), include some strength or resistance training a couple times a week, and avoid losing weight too quickly. These simple steps go a long way in protecting your lean mass while still getting all the benefits of weight loss. One study on semaglutide showed that people lost an average of about 15% of their body weight, and only around 3–4% of that was lean mass. So if someone drops 30 pounds, maybe 6 to 8 of those pounds might be lean mass—not ideal, but definitely not disastrous either, and very manageable with the right lifestyle habits.  The truth is, while some lean mass loss is expected with any type of weight loss, research shows that most of the weight lost on GLP-1s is actually fat, not muscle. For example, in the STEP 1 trial, about 80% of the weight lost on semaglutide came from fat, and only about 20% from lean tissue (as we mentioned earlier).  The SURMOUNT-1 trial with tirzepatide showed similar results—significant fat loss with relatively preserved muscle, especially when paired with resistance training. And that's important, because preserving muscle during weight loss helps protect metabolism, strength, and overall health. With good nutrition and movement, GLP-1s can lead to healthier body composition—not just a lower number on the scale. Okay, moving along to the next myth … Myth #2: GLP-1s Can Cause Blindness The truth: This myth stems from concerns about diabetic retinopathy worsening, which is tied to how quickly blood sugar drops, not to the drug itself. In the SUSTAIN-6 trial (Marso et al., NEJM, 2016), a small subset of patients with pre-existing advanced diabetic retinopathy saw transient worsening—but only in those with rapid improvements in A1c. No increased rates of blindness or new-onset retinopathy have been found in non-diabetic patients using GLP-1s for weight loss. The bottom line is that those without advanced diabetic eye disease, there's no increased risk of blindness. Patients with diabetic retinopathy should be monitored closely—but this is about glycemic management, not a direct effect of the medication. Myth #3: GLP-1s Cause Kidney or Liver Damage The truth: This is false. In fact, GLP-1 agonists may protect kidney and liver function—especially in patients with diabetes or fatty liver disease. The most recent notable study showing kidney‑protective effects of a GLP‑1 receptor agonist is the FLOW trial, which evaluated semaglutide in people with type 2 diabetes and chronic kidney disease (CKD). This double‑blind, randomized, placebo‑controlled trial included 3,533 participants followed for a median of 3.4 years and found that semaglutide reduced the risk of major kidney‑related events—including kidney failure, substantial eGFR decline, and death from renal or cardiovascular causes—by 24% compared to placebo. A 2025 meta-analysis of multiple randomized controlled trials (11 studies, 85,373 participants) concluded that GLP‑1 receptor agonists reduced the risk of composite kidney failure outcomes by 18%, kidney failure by 16%, and all‑cause death by 12%. And let's not forget the SMART trial, involving obese patients with kidney disease but without diabetes, found that semaglutide protected kidney function in this non‑diabetic, CKD‑affected population.  When it comes to the liver, there's actually growing evidence they're actually helping reverse non-alcoholic fatty liver disease (NAFLD). The STEP 1 MRI substudy and SURPASS-3 MRI substudy have shown people on these medications can reduce liver fat by 30 to even 50% and in some cases, completely resolve liver inflammation — that more serious form called NASH, where fat is combined with inflammation and early scarring. The LEAN trial found that nearly 60% of people taking semaglutide had resolution of NASH, without worsening their liver scarring. That's huge. And even better, we're seeing these effects even in people who don't have diabetes. Just losing weight helps fatty liver, but these meds seem to do more than that — they actually target inflammation and fat storage in the liver itself.. The bottom line is GLP-1s are not nephrotoxic or hepatotoxic. In fact, they may be organ-protective—especially for people with underlying metabolic issues. Myth #4: These Drugs Lead to Bone Loss The claim: “You'll get osteoporosis from losing too much weight!” The truth: While extreme weight loss can affect bone density, GLP-1s themselves do not cause bone loss, and may even have neutral or protective effects on bone. A 2022 study in Bone found no significant change in BMD (bone mineral density) in adults treated with semaglutide for obesity. While the SUSTAIN and PIONEER programs found no increased risk of fractures in semaglutide-treated patients versus placebo. Truly, concerns about bone loss are more relevant in extreme calorie restriction or eating disorders—not evidence-based GLP-1 treatment with appropriate nutrition. Myth #5: Everyone Gets Gastroparesis The claim: “These medications paralyze your stomach” The truth: GLP-1s slow gastric emptying, which is part of how they work—making you feel full longer. But this is dose-dependent and typically reversible. A 2023 FDA safety review found that true gastroparesis is extremely rare and resolves when the drug is stopped. Reality check: Nausea, early satiety, and mild bloating are common but manageable side effects. True, lasting gastroparesis is not typical, especially when doses are titrated gradually. Myth #6: GLP-1s Make Your Hair Fall Out The claim: “You'll lose a ton of hair—just like with crash diets” The truth: Hair shedding is not directly caused by GLP-1 medications. Instead, it's often a temporary, non-scarring condition called telogen effluvium, which can happen with any rapid weight loss, regardless of the method. A 2023 analysis from the American Academy of Dermatology emphasized that telogen effluvium is common with surgical or medical weight loss, especially if patients lose more than 10% of their body weight within a few months. In clinical trials like STEP and SURMOUNT, hair loss was not listed as a common side effect, but patient-reported data show it occurs occasionally—likely tied to nutritional stress, not the drug itself. So why does hair loss happen? We've talked about this before, but I don't want to leave this important information out.  Hair follicles are sensitive to internal stress. Rapid changes in caloric intake, nutrient levels (like iron, zinc, and biotin), or hormone balance can push hairs into the shedding phase. This is a delayed effect, often showing up 2–3 months after weight loss begins, and it typically resolves within 6–12 months. What helps is slower, sustained weight loss, prioritizing protein intake, supplementing iron, zinc, and biotin if deficient, and avoiding very low-calorie diets and over-restriction. Myth #6: GLP-1s Cause Dehydration It's a common myth that GLP-1 medications cause dehydration — but that's not exactly true. The medication itself doesn't directly dehydrate you. What can happen is that some people experience nausea, vomiting, or a reduced appetite early on, which can lead to drinking less water without realizing it. That's where the dehydration risk comes in. A good general rule for staying hydrated is to aim for half your body weight in ounces of water per day. So, for example, if you weigh 160 pounds, try to drink around 80 ounces daily — more if you're active or live in a hot climate. Electrolytes can also be really helpful, especially if you're feeling tired, dizzy, or crampy. I like LMNT packets — they're a clean option with no sugar and a good balance of sodium, magnesium, and potassium. The sodium in LMNT packets helps keep you hydrated by pulling water into your cells and helping your body retain the fluids it needs to function properly. Just one a day can make a big difference in how you feel. Myth #7: You Have to Stay on GLP-1s Forever or You'll Gain All the Weight Back The claim: “As soon as you stop taking it, all the weight comes back” The truth: Yes—some weight regain is likely after stopping GLP-1 medications. But that doesn't mean they're ineffective or that you're doomed to rebound completely. The same pattern happens after any type of weight loss intervention, whether it's a diet, surgery, or medication. The STEP 4 trial (Wilding et al., 2022) showed that participants who stopped semaglutide after 20 weeks regained an average of 6% of their weight loss over the next year. But it's important to note that they still weighed less than at baseline—and many continued to experience improvements in blood pressure, cholesterol, and insulin sensitivity. Similarly, in SURMOUNT-4, patients who stopped tirzepatide also regained weight, but less than they lost. So why does this weight gain happen? I feel like the answer to this is obvious, but I've found that it's not.  GLP-1s change your appetite and hunger cues. Once the medication is stopped, your body's baseline hunger signals return—and often with increased intensity, due to metabolic adaptation. But this isn't unique to GLP-1s. The same thing happens after crash diets, keto, intermittent fasting, or bariatric surgery if long-term changes aren't made. The real issue isn't the drug—it's the lack of a plan after the drug. To help make results sustainable, we need to use the medication as a tool, not a crutch. We should use it to help us lose weight and understand our hunger cues, while transitioning to a whole foods, protein based diet coupled with resistance training to help preserve and build muscle.  Just remember, if you're coming off a GLP-1 and want to keep the momentum going, the key is to approach it thoughtfully. Tapering slowly under medical supervision can help your body adjust and reduce the chances of weight regain. At the same time, this is a great moment to double down on the habits that helped you feel your best while on the medication. Think ongoing support—like working with a health coach, joining a support group, or even doing behavioral therapy—to help reinforce those long-term lifestyle changes. It's not just about what you stop; it's about what you keep doing that matters most. You don't necessarily have to stay on GLP-1s forever—but if you stop without a plan, some weight regain is very likely. Think of them like glasses: they help you see clearly while you build the habits to eventually navigate without them. For some, that may mean staying on a lower maintenance dose long-term—just like with blood pressure or cholesterol meds. What are my final thoughts? I want to be clear—GLP-1s aren't magic. But they are powerful tools when paired with education, support, and smart lifestyle changes.  Myths like ‘you'll go blind,' ‘you'll lose all your hair,' or ‘you'll be stuck on these meds forever' aren't just misleading and downright false—they discourage people from getting real help.  So if you're thinking about these medications, get informed, ask the hard questions, and make your decision based on science—not fear. Thank you for listening to The Peptide Podcast. If you enjoyed the show and want to support what we do, head over to our Partners Page. You'll find some amazing brands we trust—and by checking them out, you're helping us keep the podcast going.  Until next time, be well, and as always, have a happy, healthy week.

Tirzepatide and other GLP-1 medications can be helpful for improving metabolism, but they work best when used thoughtfully. Short-term or low-dose use, combined with balanced hormones, good nutrition, and regular exercise, can lead to better body composition and overall health. Relying on these medications alone especially at a young age can create unnecessary risks and overlook the real lifestyle changes needed for lasting results.Instead of focusing only on the number on the scale, the goal should be to build muscle, reduce excess fat, and give the body the nutrients it needs. For older adults with long-term metabolic issues, a personalized plan that includes GLP-1 therapy, supplements, and strength training can make a big difference. Used as part of a healthy routine rather than a quick fix, these medications can be a valuable tool in supporting long-term wellness.Highlights of the Podcast00:00 – Short-Term vs. Long-Term Use01:23 – Lack of Long-Term Data & Risk of Dependence04:02 – Microdosing for Older Adults05:21 – Realistic Recovery for the Metabolically Broken06:34 – Importance of Personalized Dosing09:18 – Younger Adults Should Focus on Lifestyle First11:36 – Long-Term Caution for Younger Users12:58 – Diet and Hormone Interaction14:09 – Foundation Before Medication16:28 – Responsibility in Supporting the Body

Why does joy feel so scary? Why do we hold back when life is good, waiting for something bad to happen? In this episode, I'm sharing why joy is the most vulnerable emotion we can feel and how that fear keeps us from fully living. We'll talk about why our brains default to “what if it all goes wrong,” how this ties into body image and weight loss, and why you don't need a smaller body to feel joy right now.I'm also giving you a personal update from my birthday and what's making me grateful (and a little nervous!) in this season of life. If you've ever struggled to let yourself be happy without guilt or fear, this one's for you.What you'll learn in this episode: ✔ Why joy is the most vulnerable emotion ✔ How fear of losing happiness sabotages your peace ✔ The connection between body image, weight loss, and joy ✔ Practical tips to embrace joy without waiting for the “perfect” moment

Welcome to a special episode of The Common Sense MD from Performance Medicine! Dr. Rogers sits down with Bo McGregor, FNP for an eye-opening conversation about two of today's game-changing tools in metabolic and hormonal health: testosterone and tirzepatide.Bo shares his personal journey from critical care and ER medicine to a holistic, patient-centered approach—and why he believes he finally found his calling. Together, Dr. Rogers and Bo dig into the myths and realities of hormone replacement (for men AND women), the evolving science behind testosterone therapy, and how misleading traditional nutritional advice set generations on the wrong path.They also unpack the revolutionary impact of tirzepatide for weight loss, metabolic health, and even "turning off food noise," debunking the idea that willpower alone is enough. Listen for practical tips on maximizing these therapies, why muscle-building and protein are crucial at any age, and how lifestyle changes alongside medical intervention can help you reclaim health and longevity.If you're looking for real, evidence-based advice on aging well, getting off unnecessary medications, and living vibrantly, this episode is for you.Highlights:- Debunking testosterone and hormone therapy myths - How tirzepatide is changing obesity and metabolic care - Practical advice for sustainable weight loss and muscle health - Why patients deserve (and can achieve) vitality and feeling "normal" again - The power of integrative, patient-first medicine Disclaimer: This episode does not constitute official medical advice. Please consult a licensed healthcare provider for personalized care.What did you think of this episode of the podcast? Let us know by leaving a review!Connect with Performance Medicine!Check out our new online vitamin store:⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://performancemedicine.net/shop/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Sign up for our weekly newsletter: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://performancemedicine.net/doctors-note-sign-up/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Facebook: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@PMedicine⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠@PerformancemedicineTN⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Performance Medicine

Dr. Centor discusses outcomes in patients with inadequately controlled type 2 diabetes when the dulaglutide dose is escalated versus switching to tirzepatide.

In first-ever study, keto diet scores vs. Parkinson's; Walk away from dementia; Loneliness can kill, but negative social ties can hasten biological aging; Researchers isolate potent memory compound from sage, rosemary; Sketchy knockoff weight loss drugs are flooding the marketplace; The popular vitamin you shouldn't take for sarcoidosis; When osteoporosis is so severe that even minor trauma causes rib fractures.

Titrate, Train, Triumph

Empaveli approved to treat two rare kidney diseases; Elevidys available again for ambulatory patients; Mounjaro shows benefit in cardiovascular disease; wearable cardiac monitor gets clearance; upadacitinib trial shows hair regrowth in individuals with alopecia areata.

In this conversation, I sit down with Nick to unpack the deeper science behind GLP-1s and metabolic health. We explore how compounds like Tirzepatide and GLP-1 agonists go beyond weight loss, influencing everything from cardiovascular elasticity and neuroinflammation to mood, cognition, and gut-brain signaling. We also discuss lesser-known drivers of real change, like adiponectin, MPO, and the surprising effects of statins on inflammation.But the conversation doesn't stop with human health. We dive into the behavioral power of the microbiome, how dogs might reduce childhood allergies, and whether AI can actually translate what your pet is thinking. If you're curious about fat loss, brain health, and the future of metabolic science, this episode offers a perspective you won't find anywhere else.*Chapters:*0:00 – Meet Dr. Nick: From Patient to Pioneer06:50 – The Problem with "Evidence-Based Medicine"10:15 – Why Nick Left the Medical System13:10 – Can YouTube Have a Bigger Impact Than Hospitals?16:30 – What Is Metabolic Health & Why Does It Matter?19:00 – Mental Health, Depression & Metabolism24:15 – Brain Hacks That Actually Work40:00 – Improving Metabolic Flexibility Naturally46:00 – Gut-Brain Connection & Fiber Myths*Nick's Socials + Website*IG: https://www.linkedin.com/in/nicknorwitz/Youtube channel: https://www.youtube.com/channel/UCLTZUJSEulehPtF_ytFiU_AWebsite: https://www.nicknorwitz.com*Kayla's Socials + Website*Instagram: https://www.instagram.com/kaylabarnes/TikTok: https://www.tiktok.com/@femalelongevityTwitter: https://x.com/femalelongevityWebsite: https://www.kaylabarnes.comFollow Her Female Protocol: https://www.protocol.kaylabarnes.comBecome a Member of Kayla's Female Longevity Membership: https://kayla-barnes-lentz.circle.so/checkout/become-a-member

Send us a textWelcome back Rounds Table Listeners! In this throwback episode, Drs. Mike and John Fralick chat about five important research studies published in 2024:Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (FINEARTS-HF) (0:00 – 4:09)Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity (SURMOUNT-OSA) (4:10 – 9:28)Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes (FLOW) (9:29 – 14:23)Tirzepatide for Metabolic-Dysfunction Associated Steatohepatitis with Liver Fibrosis (SYNERGY-NASH) (14:24 – 20:28)Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream Infections (BALANCE) (20:29 – 23:59)And for the Good Stuff:Toronto Star Santa Claus Fund, Calgary Food Bank, Epilepsy Canada (24:00 - 25:23)Calling keen trainees!Trainees, med students, residents: The Rounds Table and Trial Files (https://trialfiles.substack.com/) are looking for keen individuals to support our efforts.Reach out to fralickmpf@gmail.com if you are interested in getting involved. Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods

In this podcast accompanying the August issue of DTB (https://dtb.bmj.com/content/63/8), David Phizackerley (DTB Editor) is joined by James Cave (former DTB Editor-in-Chief). David and James discuss an editorial generated by artificial intelligence (AI) (https://dtb.bmj.com/content/63/8/114) which looks at the role of AI in publishing. They talk about a DTB Forum article (https://dtb.bmj.com/content/63/8/115) that explores some of the practical problems of implementing drug safety alerts.  A DTB Select article (https://dtb.bmj.com/content/63/8/117) provides an overview of a double-blind, randomised, placebo-controlled trial of tirzepatide for weight reduction in people without diabetes. They finish by reviewing the main article (https://dtb.bmj.com/content/63/8/118) that provides an overview of the evidence for lecanemab for the treatment of mild cognitive impairment and mild dementia due to Alzheimer's disease.   Link BMJ policy on AI use: https://www.bmj.com/content/ai-use 

In this episode, Dr. Melody joins the show to discuss the critical role hormones play in weight loss, particularly for women aged 35 to 65. The conversation delves into the misconceptions surrounding hormone replacement therapy and the benefits of using hormones appropriately to support health and well-being.

n this episode, I sat down with my friend and fellow coach, Jess Stancil, to break down all things peptides—what they are, how they work, when to use them, and when not to.We covered:What peptides actually are (and why not everything labeled a peptide really is one)Common options for gut health, inflammation, autoimmune symptoms, cognition, and fat loss—like BPC-157, KPV, TB500, GHK-Cu, and moreWhy peptides aren't a magic fix and should be used as short-term tools—not long-term crutchesOur thoughts on popular GLP-1s like Ozempic and Tirzepatide, plus the potential pros/cons and why dosing, context, and lifestyle matter so muchPeptides for sleep, brain fog, ADHD, and burnout (like Selank and Semax)Where people go wrong with peptide use, especially in the bodybuilding world or when chasing quick fixesAnd how to think about long-term health first—even if performance or fat loss is your goalThis one was a deep dive, but so helpful if you've been curious about peptides and whether they have a place in your health or fitness journey.

The VENTOUX study of endurance athletes, the 10,000 step myth was not busted, rate vs rhythm control for AF, and GLP1 drugs and observational studies are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Endurance Athletes and Arrhythmia (again) VENTOUX trial https://www.ahajournals.org/doi/10.1161/CIRCIMAGING.125.018470 II Daily Step Count and Health — no myths were busted. Lancet Public Health: https://doi.org/10.1016/S2468-2667(25)00164-1 III Rate vs Rhythm Control of AF Medscape: Everyone Deserves a Shot at the American Dream: Sinus Rhythm https://www.medscape.com/viewarticle/everyone-deserves-shot-american-dream-sinus-rhythm-2025a1000jle This Week in Cardiology, July 11, 2025 https://www.medscape.com/viewarticle/1002704 AFFIRM trial https://www.nejm.org/doi/full/10.1056/NEJMoa021328 AFFIRM substudy https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/486560 IV GLP-1 Drugs and Observational Studies Neurodegeneration and Stroke After Semaglutide and Tirzepatide https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2836412 SUSTAIN-6 https://www.nejm.org/doi/full/10.1056/NEJMoa1607141 SELECT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2307563 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

How the STEP-UP trial came to life,  and what made the 7.2mg dose possibleWhat the data actually says about weight loss and side effects at higher dosesWhy trial design, pharmacokinetics, and estimands matter more than you thinkWhat's coming next in obesity meds: duals, triples, and even antagonistsThe real talk on intermittent fasting, access issues, and preaching vs. scienceSign up for Dr. Spencer''s Clinic

If I wanted to gain back 70 pounds, I know exactly what I'd do because I've lived it. In this episode, I'm sharing the habits, behaviors, and sneaky thought patterns that kept me stuck for years…and would absolutely pack the weight back on if I let them. From zombie eating and isolating myself to living in stretchy pants and giving in to my inner fat bitch voice, we're calling it ALL out.If you've been slipping back into these patterns or feel disconnected from yourself, this episode is your wake-up call. 

New Study Alert!

In this episode of the Irresistible You podcast, we're diving into what it means to embrace your cozy or “soft life” era, without the guilt. I used to think that doing cozy things like diamond painting or relaxing at home was lazy… or worse, that stillness would lead to weight gain. I thought if it didn't make money or burn calories, it was a waste of time. But now I know better.I'm sharing how I've started doing things that pull me rather than constantly pushing myself and how that shift has helped me stop emotional eating, feel more grounded, and finally listen to my body. Cozy isn't laziness, it's restoration.If you've ever felt stuck between hustle culture and burnout, this episode is for you.

The Bodybuilding-friendly HRT Clinic - Get professional medical guidance on peptides AND optimizing your health as a man or bodybuilder: [ Pharma Test, IGF1, Tesamorelin, Glutathione, BPC, Semaglutide, Var troche, etc]https://transcendcompany.com/patient-intake-form/?ls=Nyle+NaygaWatch it: https://www.youtube.com/watch?v=6Ihq4tIzyS8&t=5618sRP Hypertrophy Training App: rpstrength.com/nylePlease share this episode if you liked it. To support the podcast, the best cost-free way is to subscribe and please rate the podcast 5* wherever you find your podcasts. Thanks for watching.To be part of any Q&A, follow trensparentpodcast or nylenayga on instagram and watch for Q&A prompts on the story  https://www.instagram.com/trensparentpodcast/Huge Supplements (Protein, Pre, Defend Cycle Support, Utilize GDA, Vital, Astragalus, Citrus Bergamot): https://www.hugesupplements.com/discount/NYLESupport code 'NYLE' 10% off - proceeds go towards upgrading content productionYoungLA Clothes: https://www.youngla.com/discount/nyleCode ‘NYLE' to support the podcastLet's chat about the Podcast:Instagram: https://www.instagram.com/trensparentpodcast/TikTok: https://www.tiktok.com/@transparentpodcastPersonalized Bodybuilding Program:  https://www.nylenaygafitness.comTimestamps:00:00:00 Intro  00:02:40 Personal Life Updates  00:04:51 Pregnancy and Lifestyle Changes  00:10:57 Early Steroid Use and Coaching  00:18:43 Sleep Schedules and Productivity  00:26:45 Bodybuilding Industry Evolution  00:27:52 Modern Bodybuilding Aesthetics  00:37:31 GLP-1 Agonists and Nutrition  00:41:37 Classic Physique and Weight Caps  00:46:51 Coaching and Knowledge Evolution  00:53:07 Family Genetics and Hard Work  00:56:55 Diminishing Returns With Protein  01:08:23 Growth Hormone Dosing Insights  01:16:41 Insulin and GH Combinations  01:22:54 Elite Coaching and Drug Testing  01:27:17 Insulin Resistance Myths  01:32:30 Social Media Arguments01:34:38 Trenbolone and Kidney Concerns  01:39:30 Smart Drug Choices in Bodybuilding  01:49:55 Living In Thailand01:56:35 HGH Timing 02:06:30 Tirzepatide vs. Retatrutide  02:12:00 Prescriptions and Traveling02:16:58 Reversing LVH Growth  02:22:42 Estradiol Levels on Cycle  02:27:04 Anabolic Synonymous Shutdown02:30:45 Classic Physique Drug Use 02:33:40 Life Updates and Fatherhood

Are you navigating the stormy seas of menopause? Wondering how to tackle bloating and breakthrough bleeding? Curious about the mysteries of hormone therapy and why traditional treatments may not work for everyone? This second-part Q&A episode is packed with real-life stories and expert advice to answer your questions! Ever wondered how hormone levels, thyroid function, and gut health intertwine during menopause? What about the innovative strategies that can help with weight loss resistance? Discover why personalized solutions are key to thriving through hormonal shifts and learn how to biohack your way to better health. From managing stress-induced hormone fluctuations to the unexpected role of melatonin, this episode has it all. What adjustments can you make to your hormone replacement therapy during stressful times? And how can peptides help in your weight loss journey? Dive into these topics and more! In this episode, we uncover: How hormone imbalances can cause bloating, plus how to address them effectively. Why personalized hormone therapy is crucial for women with unique health challenges. How innovative peptides can help overcome weight loss resistance and enhance results. Why adjusting hormone therapy during stress is vital for managing menopause symptoms. How melatonin plays a multifaceted role in menopause beyond just aiding sleep. Don't miss out on these transformative insights. Tune in now to empower your journey through menopause and discover solutions that truly work for you!     Sponsors Get our Estro Vitality and Progest Sleep Hormone Oils and get 25% off. Coupon KM20 to get 20% off your order of Vitali Skin Care! Use my link to save 20% at GETKION.COM/HORMONE     Are you in peri or post menopause and looking to optimize your hormones and health? At Hormone Solutions, we offer telemedicine services and can prescribe in every U.S. state, as well as in British Columbia, Alberta, and Ontario in Canada.   Visit karenmartel.com to explore our comprehensive programs: Bioidentical Hormone Replacement Therapy Individualized Weight Loss Programs  Peptide Therapy for weight loss    Interested in our NEW Peptide Weight Loss Program? Join today and get all the details here.   Join our Women's Peri and Post Menopause Group Coaching Program, OnTrack, TODAY!   To our nursing audience members, our podcasts qualify for nursing CE @ RNegade.pro. Provide # CEP17654.   Your host: Karen Martel Certified Hormone Specialist, Transformational Nutrition Coach, & Weight Loss Expert   Karen's Facebook Karen's Instagram